Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
Delayed Quote. Delayed Nyse - 09/24 04:10:00 pm
73.61 USD   +0.77%
09/24Health Care Stocks Retreat Friday
MT
09/24Wall Street Tumbles Pre-Bell, Evergrande Risks Resurface
MT
09/24Health Care Stocks Slip Pre-Bell Friday
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

ALX Oncology Announces First Patient Dosed in ASPEN-04, a Phase 2 Study of ALX148 in Combination with KEYTRUDA (pembrolizumab) and Chemotherapy for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma

07/28/2021 | 07:00am EDT

ALX Oncology Holdings Inc. in partnership with Merck & Co., Inc. announced the first patient has been dosed in the Phase 2 ASPEN-04 study evaluating the combination of ALX148, a next generation CD47 blocker, with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, and standard chemotherapy for the treatment of patients with advanced head and neck squamous cell carcinoma. ASPEN-04 (NCT04675333) is an open-label, randomized phase 2 multi-center study of the anti-tumor efficacy of ALX148 in combination with pembrolizumab and standard chemotherapy in patients with first line metastatic or unresectable, recurrent HNSCC who have not received prior systemic therapy for their advanced disease. This study will enroll patients regardless of PD-L1 expression status. The study is being conducted in collaboration with Merck and is based on promising clinical data reported from the ASPEN-01 Phase 1 study, which provided the basis for ALX148’s Fast Track Approval in HNSCC granted by the U.S. Food and Drug Administration.


ę S&P Capital IQ 2021
All news about MERCK & CO., INC.
09/24Health Care Stocks Retreat Friday
MT
09/24Wall Street Tumbles Pre-Bell, Evergrande Risks Resurface
MT
09/24Health Care Stocks Slip Pre-Bell Friday
MT
09/24MERCK : LYNPARZA« (olaparib) in Combination With Abiraterone Significantly Delayed Disease..
BU
09/24AstraZeneca and Merck Announce Positive Results from the Phase 3 PROpel Trial
CI
09/24ASTRAZENECA : Merck & Co.'s Combination Therapy Benefits Prostate Cancer Patients in Phase..
MT
09/24ASTRAZENECA : Merck & Co.'s Prostate Cancer Drug Extends Lives in Late-Stage Study
MT
09/21MERCK : Thinking about trading options or stock in Draftkings, Merck, ConocoPhillips, Walg..
PR
09/21MERCK : Building Sustainable Value for our Business and Society
PU
09/20MERCK : KEYTRUDA (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Ris..
AQ
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2021 46 881 M - -
Net income 2021 12 645 M - -
Net Debt 2021 15 254 M - -
P/E ratio 2021 16,1x
Yield 2021 3,52%
Capitalization 186 B 186 B -
EV / Sales 2021 4,30x
EV / Sales 2022 3,89x
Nbr of Employees 73 500
Free-Float 70,7%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 73,61 $
Average target price 93,42 $
Spread / Average Target 26,9%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.-10.01%186 334
JOHNSON & JOHNSON4.44%432 675
ROCHE HOLDING AG10.16%321 605
PFIZER, INC.20.05%246 358
NOVO NORDISK A/S50.45%231 485
ELI LILLY AND COMPANY37.22%210 037